Tracking tumor DNA in blood for high-grade upper tract urothelial cancer
This study looks at blood tests to find pieces of tumor DNA (called ctDNA) in people with high-grade upper tract urothelial cancer (UTUC). It aims to see if these blood tests can help track the cancer's response to treatment or surgery, potentially guiding better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-grade upper tract urothelial cancer (cancer in the kidney or ureter).
- You must be scheduled to receive systemic therapy (like chemo or immunotherapy) or undergo surgery to remove the cancer.
- You must agree to have blood tests to check for circulating tumor DNA (ctDNA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
This trial is testing a system that helps doctors choose the best additional treatment for people with advanced upper tract urothelial cancer (UTUC) after their surgery. It focuses on patients whose cancer has spread into the muscle layer or beyond, or to nearby lymph nodes.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
This study is testing a blood test called Signatera to see if it can find leftover cancer DNA after treatment for early-stage endometrial cancer. It may help doctors decide who needs more treatment and who can safely be watched.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.